Rowan Miller

Medicine · Health Sciences

25h-index3.5kcitations213works9.72yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(91), PARP inhibition in cancer therapy(65), Chromatin Remodeling and Cancer(36), Cancer Mechanisms and Therapy(29), Endometrial and Cervical Cancer Treatments(27)

Publications213 total

Long-term outcomes in patients with platinum-sensitive recurrent ovarian cancer receiving ≥ 2 year duration of maintenance PARP inhibitor therapy
International Journal of Gynecological Cancer·2026
A ten-year retrospective analysis of the clinical outcomes of epithelial ovarian cancer patients recruited to UCLH’s early-phase trials unit.
International Journal of Gynecological Cancer·2026
Evolving management and fertility outcomes in ovarian germ cell tumours: A 27-year retrospective cohort study
International Journal of Gynecological Cancer·2026
Real-world outcomes in clear cell gynaecological cancer: impact on survival with bevacizumab-containing regimens at two UK tertiary centres
International Journal of Gynecological Cancer·2026
Real-world outcomes at 3 years follow-up of olaparib first line maintenance treatment in patients with BRCA-mutated advanced ovarian cancer: results from the United Kingdom
International Journal of Gynecological Cancer·2026
Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
2025Open Access
RACIAL SUBGROUP ANALYSES OF TUMOR RESPONSE AND SAFETY IN PATIENTS WITH MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH ADVANCED/RECURRENT ENDOMETRIAL CANCER RECEIVING DOSTARLIMAB MONOTHERAPY IN THE GARNET TRIAL
International Journal of Gynecological Cancer·2025
POST-OPERATIVE HORMONAL THERAPY VERSUS CHEMOTHERAPY IN STAGE II-IV LOW-GRADE SEROUS OVARIAN CARCINOMA: A TWO-CENTRE RETROSPECTIVE ANALYSIS
International Journal of Gynecological Cancer·2025
P-POSSUM Falls Short: Predicting Morbidity in Ovarian Cancer (OC) Cytoreductive Surgery
Cancers·2025Open Access
Ceralasertib (cerala) + olaparib (ola) in patients (pts) with homologous recombination repair (HRR)-deficient platinum-sensitive relapsed ovarian cancer (OC) after progression on prior PARP inhibitor (PARPi) treatment (tx).
Journal of Clinical Oncology·2025
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study
British Journal of Cancer·2025· 7 citedOpen Access
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial
The Lancet Oncology·2025· 14 cited
Corrigendum to “Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group”
Annals of Oncology·2025· 2 citedOpen Access
Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer
JAMA Oncology·2025· 24 citedOpen Access
Association Of Niraparib With Acute Kidney Injury In Patients With Ovarian Cancer
International Journal of Gynecological Cancer·2025
ATHENA-MONO Post-Progression Survival Data Update In Patients With Newly Diagnosed Advanced Ovarian Cancer
International Journal of Gynecological Cancer·2025Open Access
The Incidence Of Breast Cancer In Ovarian Cancer Patients With BRCA Mutations: A Multicentre Retrospective Cohort Study.
International Journal of Gynecological Cancer·2025
Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer
Therapeutic Advances in Medical Oncology·2025· 2 citedOpen Access
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer
BMJ Open·2024· 7 citedOpen Access
Current practices for the management of advanced high-grade epithelial ovarian cancer in the UK: OC-NOW survey (2023)
Future Oncology·2024· 2 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

Rebecca Kristeleit(10), Christopher J. Lord(8), Susana Banerjee(7), Jonathan A. Ledermann(6), Alan Ashworth(6), Michelle Lockley(6), James Campbell(5), Rumana Rafiq(5), Rachel Brough(5), Ilirjana Bajrami(5), Ana Oaknin(5), Jung‐Yun Lee(5), Anna V. Tinker(5), Shanthini Mary Crusz(5), Chris T. Williamson(4), Helen N. Pemberton(4), Ranjit Manchanda(4), Adriano Gravina(4), Lucy Gilbert(4), Eleftherios Zografos(4)